|Bid||0.00 x 1400|
|Ask||0.00 x 1100|
|Day's Range||3.95 - 4.13|
|52 Week Range||1.85 - 6.64|
|PE Ratio (TTM)||1.48|
|Earnings Date||Aug 9, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.55|
DOYLESTOWN, Pa., May 14, 2018-- ProPhase Labs, Inc. today reported its financial results for the three months ended March 31, 2018. Net sales from continuing operations were $3.4 million for the three ...
ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com), a vertically integrated and diversified branding, marketing and technology company with deep experience in over-the-counter dietary supplements and remedies (“ProPhase” or “Company”), announced today that its Board of Directors has declared a special cash dividend in the amount of $1.00 per share on its common stock, payable on June 5, 2018 to stockholders of record as of May 21, 2018. “We are pleased to return to our stockholders a common dividend of $1.00 per share, which represents 34.6% of its closing price of $2.89 per share as of May 7, 2018. This dividend provides an immediate benefit to our stockholders, while allowing us to remain well positioned for future growth with ample liquidity for strategic opportunities that may arise,” said Ted Karkus, Chairman and Chief Executive Officer of ProPhase.
DOYLESTOWN, Pa., March 21, 2018-- ProPhase Labs, Inc., today reported its net sales from continuing operations were $9.9 million for the year ended December 31, 2017, as compared to net sales of $4.2 million ...
NEW YORK, NY / ACCESSWIRE / March 21, 2018 / ProPhase Labs, Inc. (NASDAQ: PRPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 21, 2018 at 11:00 AM Eastern Time. ...
DOYLESTOWN, Pa., March 16, 2018-- ProPhase Labs announced today that financial results for the year ended December 31, 2017, will be released before the market opens on Wednesday, March 21, 2018. A conference ...
ProPhase Labs Inc. is buying back $4.5 million of its common stock, completing a tender offer announced earlier this month. The Doylestown, Pa., natural health products company said Thursday it has accepted for purchase about 1.95 million shares at $2.30 per share. ProPhase is the original developer of Cold-Eeze zinc lozenges for cold suffers.
ProPhase Labs Inc (NASDAQ:PRPH) delivered an ROE of 70.52% over the past 12 months, which is an impressive feat relative to its industry average of 16.15% during the same period.Read More...
Categories: Yahoo FinanceGet free summary analysis ProPhase Labs, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ProPhase Labs, Inc. – Mannatech, Incorporated, Reliv’ International, Inc., USANA Health Sciences, Inc., Nature’s Sunshine Products, Inc., Cyanotech Corporation, XOMA Corporation and True Drinks Holdings, Inc. (MTEX-US, RELV-US, ... Read more (Read more...)
ProPhase Labs Inc (NASDAQ:PRPH) is trading with a trailing P/E of 2.4x, which is lower than the industry average of 24.1x. While this makes PRPH appear like a great stockRead More...
Categories: Yahoo FinanceGet free summary analysis ProPhase Labs, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of ProPhase Labs, Inc. – Mannatech, Incorporated, Reliv’ International, Inc., USANA Health Sciences, Inc., Nutraceutical International Corporation, Nature’s Sunshine Products, Inc., Oragenics, Inc., Cyanotech Corporation and XOMA Corporation (MTEX-US, ... Read more (Read more...)
ProPhase Labs, Inc. today reported that that on June 12, 2017 it entered into a Stock Purchase Agreement with each of Mark S. Leventhal, a former director of the Company, and certain other persons and ...